T esticular leukemia may be an obstacle in the treatment of boys with acute lymphoblastic leukemia (ALL). Before 1960, testicular involvement was rarely observed. With the significant improvement of survival in the past decades, an increase in the testicular recurrence rate occurred; the reported frequency of overt testicular recurrence in children with ALL ranges between 0.9 -8.8%. 1, 2 These recurrences occur mainly during bone marrow disease remission. Because testicular recurrence, like other types of extramedullary recurrence, should be considered to be a harbinger of bone marrow recurrence, these patients receive a full retreatment regimen. In all reports studied, radiotherapy has been given to one or both testicles. In this article, the authors describe five cases in which radiotherapy could be avoided, probably by including (very) high dose methotrexate in the treatment regimen. 
RESULTS
Characteristics at diagnosis of all patients are prepresentation. In 1980 (8 months after stopping maintenance therapy) swelling of the left testicle was noted; sented in Table 1 . A summary of treatment of the recurrence is given in 3 Essentially, a standard induction treatment was used, and CNS prophylaxis was given ate (6000 mg/m 2 ) were given. This maintenance treatment was similar to the maintenance treatment used using radiotherapy; no methotrexate was given. In 1987, 71 months after stopping antileukemic treatafter the initial treatment; however, 6 additional infusions of methotrexate (6000 mg/m 2 ) were added at ment, the patient developed right testicular enlargement, which was proven to be a recurrence of the monthly intervals. Treatment was stopped in 1982, 24 months after reinduction therapy was started. Pubertal original disease. No other sites were involved. Treatment was essentially the same as reported in Case 2. development has been normal. At last follow-up, the volumes of both testicles were alike and of normal Treatment for the local recurrence started with high dose methotrexate (12,000 mg/m 2 in a single 6-hour adult size. The patient's plasma testosterone level was normal (18.1 mM/L) and luteinizing hormone (LH) and infusion) and was combined with teniposide (165 mg/ m 2 2-hour infusion) and Ara-C (1000 mg/m 2 1-hour follicle-stimulating hormone (FSH) were not elevated (5.0 U/L and 4.0 U/L; reference values õ 15 U/L for infusion), given on the same day. Systemic reinduction was started after 1 week and was comprised of predniboth LH and FSH). His sperm count was 31 1 10 6 / mL.
solone ( courses with 6-mercaptopurine (50 mg/m 2 /day orally) and methotrexate, as outlined in the report for Case and methotrexate (30 mg/m 2 /week orally) were given. 1. Therapy was stopped 24 months after initial presenTreatment was stopped in 1988, 12 months after diagtation. In 1991 (19 months after stopping maintenance nosis of recurrence. Pubertal development has been therapy) swelling of both testicles was noted; histology normal. At last follow-up, the patient's plasma testosrevealed infiltration with lymphoblasts. Immunologic terone level was normal (24 mM/L), and LH and FSH markers were similar to those observed in the were not elevated (4.0 U/L and 7.0 U/L). Volumes of lymphoblasts at initial diagnosis. Bone marrow and both testicles were alike and they were of normal adult cerebrospinal fluid were normal. At the start of treatsize. A sperm count of 2.3 1 10 6 mL was noted. ment, 1 6-hour infusion with methotrexate (12,000 mg/m 2 ) was given. Cytosine arabinoside (Ara-C) (1000 Case 4 mg/m 2 1-hour infusion) and teniposide (165 mg/m 2 2-Initial treatment was given according to Protocol VI of hour infusion) were given in Weeks 3 and 11. Systemic DCLSG. 4 Essentially, a standard induction treatment reinduction was started 4 weeks after start of treatand CNS prophylaxis using methotrexate was given. ment for the testicular localization and was comprised Treatment was given according to the standard risk factor for outcome after isolated testicular recurrence is the duration of first remission. An especially bad regimen of the ALL-BFM 86 protocol. 5 Treatment was given for 18 months. In 1994, 22 months after the end prognosis exists if the recurrence occurs while the patient is still undergoing chemotherapy. 18-20 Current of initial treatment, a recurrence in the right testicle was histologically confirmed. Therapy to treat this retreatment protocols for testicular recurrence invariably contain radiotherapy, mainly for both testes.
7, 14 - currence was similar to the treatment for recurrence in Case 4. At last follow-up, pubertal development was 17, 19, 21 The cases in the current study show that there is at least a subpopulation of boys with testicular rebeginning at the age of 15 years. The patient's testicular volumes were alike and both testicles showed norcurrence who can be treated with high dose methotrexate without radiotherapy, thus salvaging the testes. mal pubertal growth (5 mL at latest examination).
However, the follow-up period in the patients in Cases 4 and 5, considering the duration of first remission is
DISCUSSION
Advances in the management of childhood leukemia too short to state that cure has already been ascertained. have introduced new problems and new questions, and the significance of testicular leukemia is currently With regard to the role of routine biopsy, Wofford et al. showed that a positive biopsy at the end of initial under debate. Some have regarded the testes, like the CNS, as a sanctuary wherein leukemic cells are relatherapy is indicative of a poorer prognosis. 17 However, comparing these patients with the cases in the current tively protected from chemotherapeutic agents and from which place they may reseed the bone marrow. 6, 7 study, it is likely that their patients would have developed an earlier recurrence. As such their results canOthers consider the testes as merely a barometer of extramedullary disease, foretelling generalized recurnot be used for patients with late recurrences. In addition, Buchanan et al. showed that seven of nine parence. 8 Recent investigations using polymerase chain reactions (PCR) for leukemia specific sequences have tients with an isolated testicular recurrence had negative routine biopsies at the end of antileukemic shown that malignant cells can already be present in the bone marrow at the moment of extramedullary treatment. 16 The role and scheduling of sonography of the testicles to detect recurrences that are not yet recurrence, although microscopically the bone marrow is still in remission. 9 Although quantification by palpable is questionable. Because no early testicular recurrences were noted in the patients in the current PCR is not yet totally reliable, figures of 0.1 -1.0% are mentioned in regard to the extent of bone marrow study, the authors cannot make any conclusions regarding patients with early isolated recurrences. It has infiltration.
10,11 Clinical observations (i.e., 1) boys with testicular recurrence treated only locally, by means been shown that methotrexate easily reaches the testicular interstitium. 22 The clinical efficacy of high dose of radiotherapy, develop a bone marrow recurrence within a few months and 2) the finding of patients methotrexate to eradicate leukemic foci in the testes is reflected by the fact that the use of intermediate with apparently isolated testicular leukemia showing spread to abdominal lymph nodes as verified on samdose methotrexate in first-line treatment protocols has significantly decreased the frequency of testicular reples taken at laparotomy) add to the assumption that testicular leukemia must be considered part of the currence. [23] [24] [25] [26] [27] [28] [29] From the literature, one can conclude that the authors' mode of treatment is probably relageneralized disease.
12,13 Consequently, systemic retreatment is needed. Using modern regimens, another tively safe with regard to side effects to the testicle. No killing of the stem cells of spermatogenesis by the recurrence is still the major event after treatment of isolated testicular recurrence. Combining 5 major recytostatic agents used has been described in animals.
30
Only in rats treated with Ara-C in the neonatal period ports (i.e., BFM Rez 85, AIEOP, POG 8303, POG 8304, CCG-112), 109 of 231 patients experienced a second the number of Sertoli's cells did decrease. 31 The occurrence of DNA breaks during spermatogenesis as a rerecurrence; in 82 patients, the bone marrow was the not mandatory in the treatment of a first isolated late 13 . Baum E, Heyn R, Nesbit M, Tilford D, Nachman J. Occult testicular recurrence in patients with ALL.
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